Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase–producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis
- 38 Downloads
Cefoxitin has demonstrated good in vitro activity against extended spectrum beta-lactamase (ESBL)–producing Escherichia coli (ESBL-Ec) and is regarded as a carbapenem-sparing beta-lactam alternative in urinary tract infections. Its efficacy has never been compared to carbapenems in male UTIs. Our study aimed to compare the clinical and microbiological efficacy of cefoxitin (FOX) and carbapenems (CP) in febrile M-UTI due to ESBL-Ec (F-M-UTI). We conducted a multicenter retrospective cohort study of patients with F-M-UTI treated with FOX or CP as definitive therapy, between January 2013 and June 2015, in six French acute care teaching hospitals. The clinical and microbiological efficacies of FOX and CP were compared using multivariable logistic regression models, adjusting for propensity scores. Of the 66 patients included, 23 patients in FOX group and 27 in CP group had clinical assessment at follow-up. Median follow-up after end of treatment was 63 days (interquartile range 26–114). Clinical success was observed for 17/23 (73.9%) and 22/27 (81.5%) patients and microbiological success for 11/19 (57.9%) and for 6/12 (50.0%) patients in FOX and CP groups respectively. We did not find any significant difference for clinical (OR = 0.90, 95% CI [0.12; 6.70]) neither microbiological (OR = 0.85, 95% CI [0.05; 14.00]) success between CP and FOX groups in univariate and multivariable models. In the FOX group, high dose with use of continuous infusion was associated with clinical success. These results add evidence that FOX is an effective alternative treatment to carbapenems for M-UTI caused by ESBL-Ec, particularly when high doses and continuous infusion are used.
KeywordsCefoxitin Cephamycin Carbapenem sparing Urinary tract infection Prostatitis Extended spectrum beta-lactamase–producing Escherichia coli Continuous infusion
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All the procedures were in accordance with the 1964 Helsinki Declaration and its later amendments.
According to French Health Public Law (CSP Article L1121-1), this type of study did not require specific informed consent or ethics committee approval.
- 1.Etienne M, Chavanet P, Sibert L, Michel F, Levesque H, Lorcerie B, Doucet J, Pfitzenmeyer P, Caron F (2008) Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis 8:12. https://doi.org/10.1186/1471-2334-8-12 CrossRefGoogle Scholar
- 4.Harris PN, Tambyah PA, Paterson DL (2015) Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 15(4):475–485. https://doi.org/10.1016/s1473-3099(14)70950-8 CrossRefGoogle Scholar
- 5.Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL (2004) Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39(1):31–37CrossRefGoogle Scholar
- 7.Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruyere F, Cariou G, Clouqueur E, Cohen R, Doco-Lecompte T, Elefant E, Faure K, Gauzit R, Gavazzi G, Lemaitre L, Raymond J, Senneville E, Sotto A, Subtil D, Trivalle C, Merens A, Etienne M (2018) Practice guidelines for the management of adult community-acquired urinary tract infections. Med Mal Infect. https://doi.org/10.1016/j.medmal.2018.03.005
- 10.Lepeule R, Leflon-Guibout V, Vanjak D, Zahar JR, Lafaurie M, Besson C, Lefort A (2014) Clinical spectrum of urine cultures positive for ESBL-producing Escherichia coli in hospitalized patients and impact on antibiotic use. Med Mal Infect 44(11–12):530–534. https://doi.org/10.1016/j.medmal.2014.09.004 CrossRefGoogle Scholar
- 13.Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ (2002) Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137(10):791–797CrossRefGoogle Scholar
- 14.European Manual of Clinical Microbiology (2012)Google Scholar
- 15.Bonnet RCJ, Chardon H, Chidiac C, Courvalin P, Dabernat H (2013) Recommendations of Antibiogram Committee. In: French Society for Microbiology, p 58Google Scholar
- 17.Lepeule R, Ruppe E, Le P, Massias L, Chau F, Nucci A, Lefort A, Fantin B (2012) Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15 type extended-spectrum beta-lactamase. Antimicrob Agents Chemother 2012:3Google Scholar
- 19.Kerneis S, Valade S, Geri G, Compain F, Lavollay M, Rostane H, Carbonnelle E, Mainardi JL (2015) Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis (Lond) 47(11):789–795. https://doi.org/10.3109/23744235.2015.1062133 CrossRefGoogle Scholar
- 20.Mambie A, Vuotto F, Poitrenaud D, Weyrich P, Cannesson O, Dessein R, Faure K, Guery B, Galperine T (2016) Cefoxitin: an alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Med Mal Infect 46(4):215–219. https://doi.org/10.1016/j.medmal.2016.04.008 CrossRefGoogle Scholar
- 21.Demonchy E, Courjon J, Ughetto E, Durand M, Risso K, Garraffo R, Roger PM (2018) Cefoxitin-based antibiotic therapy for extended-spectrum beta-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study. Int J Antimicrob Agents 51(6):836–841. https://doi.org/10.1016/j.ijantimicag.2018.01.008 CrossRefGoogle Scholar
- 22.Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S (2015) Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother 59(9):5107–5113. https://doi.org/10.1128/aac.00701-15 CrossRefGoogle Scholar
- 25.Lee CH, Chu C, Liu JW, Chen YS, Chiu CJ, Su LH (2007) Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother 60(2):410–413. https://doi.org/10.1093/jac/dkm215 CrossRefGoogle Scholar
- 27.Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, Bille E, Jullien V, Zahar JR (2014) Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 58(8):4899–4901. https://doi.org/10.1128/aac.02509-14 CrossRefGoogle Scholar
- 31.Woerther PL, Lepeule R, Burdet C, Decousser JW, Ruppe E, Barbier F (2018) Carbapenems and alternative beta-lactams for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation resistance? Int J Antimicrob Agents 52(6):762–770. https://doi.org/10.1016/j.ijantimicag.2018.08.026 CrossRefGoogle Scholar
- 32.Armand-Lefevre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppe E, Bronchard R, Lepeule R, Lucet JC, El Mniai A, Wolff M, Montravers P, Plesiat P, Andremont A (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–1495CrossRefGoogle Scholar